Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ctrv.2015.03.008 http://scihub22266oqcxt.onion/10.1016/j.ctrv.2015.03.008 25869102/?report=reader!4426229!25869102     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Treat+Rev 2015 ; 41 (5): 391-400 Nephropedia Template TP {{tp|p=25869102|t=2015. Targeted therapies for advanced Ewing sarcoma family of tumors |pdf=|usr=}}{{25869102}} gab.com Text Targeted therapies for advanced Ewing sarcoma family of tumors JO: Cancer Treat Rev http://www.kidney.de/pget.php?&tw=1&pmid=25869102 #FOAvip The prognosis of adolescent and young adult patients battling metastatic Ewing sarcoma family of tumors (ESFT) remains less than 30% despite the development of systemic therapies. In the era of personalized medicine, novel molecular targets have been tested in preclinical or clinical settings in ESFT. In this review, we focus on early clinical and translational research that identified multiple molecular targets, including IGF-1R; mTOR; tyrosine kinase inhibitors; EWS-FLI1-related targets, and others. Overall, novel targeted therapies demonstrated modest efficacy; however pronounced and durable antineoplastic responses have been observed in small subsets of treated patients, for example with IGF-1R antibodies. Identifying outcome-predicting biomarkers and overcoming treatment resistance remain major challenges. Due to the rarity of ESFT, multi-institutional collaboration efforts of clinicians, basic and translational scientists are needed in order to understand biology of therapeutic response or resistance, which can lead to development of novel therapeutic methods and improved patient outcomes. Twit Text FOAVip Targeted therapies for advanced Ewing sarcoma family of tumors ????Cancer Treat Rev http://www.kidney.de/pget.php?&tw=1&pmid=25869102 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25869102 #FOAvip English Wikipedia <ref>{{Cite pmid|25869102}}</ref> Targeted therapies for advanced Ewing sarcoma family of tumors #MMPMID25869102 Jiang Y; Ludwig J; Janku F Cancer Treat Rev 2015[May]; 41 (5): 391-400 PMID25869102show ga The prognosis of adolescent and young adult patients battling metastatic Ewing sarcoma family of tumors (ESFT) remains less than 30% despite the development of systemic therapies. In the era of personalized medicine, novel molecular targets have been tested in preclinical or clinical settings in ESFT. In this review, we focus on early clinical and translational research that identified multiple molecular targets, including IGF-1R; mTOR; tyrosine kinase inhibitors; EWS-FLI1-related targets, and others. Overall, novel targeted therapies demonstrated modest efficacy; however pronounced and durable antineoplastic responses have been observed in small subsets of treated patients, for example with IGF-1R antibodies. Identifying outcome-predicting biomarkers and overcoming treatment resistance remain major challenges. Due to the rarity of ESFT, multi-institutional collaboration efforts of clinicians, basic and translational scientists are needed in order to understand biology of therapeutic response or resistance, which can lead to development of novel therapeutic methods and improved patient outcomes. |*Molecular Targeted Therapy[MESH] |Antineoplastic Agents/*therapeutic use[MESH] |Bone Neoplasms/*drug therapy[MESH] |Humans[MESH]Targeted therapies for advanced Ewing sarcoma family of tumors (epmc).pdf DeepDyve Pubget Overpricing